Neuronetics Deal To Acquire Greenbrook TMS Gains Final Approvals

The Ontario Superior Court of Justice granted final approval of a previously announced arrangement in which Neuronetics, Inc. will acquire Greenbrook TMS in an all-stock transaction. The deal was initially announced on August 12, 2024, and with this final approval is expected to close by the end of November 2024. Neuronetics manufactures the Neurostar transcranial magnetic stimulation (TMS) system, a non-drug, noninvasive treatment for depression, anxiety, and obsessive-compulsive disorder. About Greenbrook TMS operates 130 mental health treatment centers that offer TMS treatment and other center-based services to treat depression and other mental health disorders. By combining . . .